[go: up one dir, main page]

ES2117249T3 - Derivados de 2,6-diaminopurina. - Google Patents

Derivados de 2,6-diaminopurina.

Info

Publication number
ES2117249T3
ES2117249T3 ES94905100T ES94905100T ES2117249T3 ES 2117249 T3 ES2117249 T3 ES 2117249T3 ES 94905100 T ES94905100 T ES 94905100T ES 94905100 T ES94905100 T ES 94905100T ES 2117249 T3 ES2117249 T3 ES 2117249T3
Authority
ES
Spain
Prior art keywords
sub
sup
diaminopurine
derivatives
cyclloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94905100T
Other languages
English (en)
Inventor
Michael Gregson
Barry Edward Ayres
George Blanch Ewan
Frank Ellis
John Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2117249T3 publication Critical patent/ES2117249T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE DESCRIBEN LOS DERIVADOS DE LA 2,6-DIAMINOPURINA- BE -DRIBOFURANURONAMIDA QUE TIENEN LA FORMULA GENERAL (I) Y SALES Y SOLVATOS DE LOS MISMOS, EN LA QUE: R{SUP,1} ES HIDROGENO, C{SUB,3-8}CICLOALQUILO O C{SUB,1-6}ALQUILO; R{SUP,2} ES C{SUB,38}CICLOALQUILO, C{SUB,3-8}CICLOALQUILOC{SUB,1-6}ALQUILO, ALQU{SUB,1}Y,-(CHR{SUP,5}){SUB,M}(ALK{SUB,2}){SUB,N}Z O APROPIADAMENTE SUSTITUIDO C{SUB,3-8}CICLOALQUILO, C{SUB,38}CICLOALQUILC{SUB,1-6}ALQUILO, PIRROLIDINA-3-YL, 2OXOPIRROLIDINA-4-YL, 2-OXOPIRROLIDINA-5-YL, PIPERIDINA-3-YL O PIPERIDINA-4-YL, Y Q ES OXIGENO O SULFURO. COMPUESTOS DE LA FORMULA (I) Y SUS SALES Y SOLVATOS TIENEN USO EN MEDICINA COMO AGENTES ANTI-INFLAMATORIOS, PARTICULARMENTE EN EL TRATAMIENTO DE PACIENTES EN SITUACIONES INFLAMATORIAS QUE SON SUSCEPTIBLES DE DAÑOS EN EL TEJIDO INDUCIDO POR LEUCOCITOS.
ES94905100T 1993-01-20 1994-01-18 Derivados de 2,6-diaminopurina. Expired - Lifetime ES2117249T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939301000A GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2117249T3 true ES2117249T3 (es) 1998-08-01

Family

ID=10728948

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94905100T Expired - Lifetime ES2117249T3 (es) 1993-01-20 1994-01-18 Derivados de 2,6-diaminopurina.

Country Status (29)

Country Link
US (2) US5925624A (es)
EP (1) EP0680488B1 (es)
JP (1) JP3768232B2 (es)
KR (1) KR960700261A (es)
CN (1) CN1043997C (es)
AP (1) AP457A (es)
AT (1) ATE164849T1 (es)
AU (1) AU679714B2 (es)
CA (1) CA2153688A1 (es)
CZ (1) CZ187995A3 (es)
DE (1) DE69409503T2 (es)
DK (1) DK0680488T3 (es)
EC (1) ECSP941104A (es)
ES (1) ES2117249T3 (es)
FI (1) FI953489L (es)
GB (1) GB9301000D0 (es)
HU (1) HU211914A9 (es)
IL (1) IL108372A (es)
IS (1) IS4121A (es)
NO (1) NO305603B1 (es)
NZ (1) NZ259880A (es)
PE (1) PE54194A1 (es)
PL (1) PL309975A1 (es)
RU (1) RU2129561C1 (es)
SI (1) SI9400021A (es)
SK (1) SK281229B6 (es)
TW (1) TW267168B (es)
WO (1) WO1994017090A1 (es)
ZA (1) ZA94335B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237234A1 (es) * 2002-08-02 2005-07-16 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
ES2331867A1 (es) * 2008-07-17 2010-01-18 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69615020T2 (de) * 1995-05-30 2002-03-21 Aventis Pharma S.A., Antony 2-azabicyclo[2.2.1]heptan-derivate, ihre herstellung und ihre anwendung
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3861413B2 (ja) * 1997-11-05 2006-12-20 ソニー株式会社 情報配信システム、情報処理端末装置、携帯端末装置
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
AU748178B2 (en) * 1998-02-26 2002-05-30 Aventis Holdings Inc. 6,9-disubstituted 2-(trans-(4- aminocyclohexyl) amino)purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
NZ508314A (en) 1998-06-02 2004-03-26 Osi Pharm Inc Pyrrolo[2,3d]pyrimidine compositions and their use
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
JP3933870B2 (ja) * 1998-06-23 2007-06-20 グラクソ グループ リミテッド ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
RU2258071C2 (ru) * 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP2003531111A (ja) 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2527754T3 (es) 2000-04-25 2015-01-29 Icos Corporation Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana
EP1939203B1 (en) * 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
AU2002319033B2 (en) * 2001-07-06 2008-01-10 Pharmaxis Ltd Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
JP4350517B2 (ja) * 2001-11-09 2009-10-21 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニスト
JP4493337B2 (ja) 2001-11-27 2010-06-30 アナディス ファーマシューティカルズ インク ３−β−Ｄ−リボフラノシルチアゾロ［４，５−ｄ］ピリミジンヌクレオシド及びその使用
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
EP2050751A1 (en) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
EA007468B1 (ru) 2001-12-20 2006-10-27 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
NZ538590A (en) * 2002-08-15 2006-10-27 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0328319D0 (en) * 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Improved synthesis of 2-substituted adenosines
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
ME01072B (me) * 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
FR2874014B1 (fr) * 2004-08-03 2010-05-14 Univ Paris Descartes Analogues d'aminoglycosides, leur utilisation et leur synthese
EP1812075B1 (en) 2004-10-29 2013-12-11 Topigen Pharmaceuticals Inc. Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
KR101320008B1 (ko) 2004-12-17 2013-10-18 애나디스 파마슈티칼스, 인코포레이티드 ３，５-이치환 및 ３，５，７-삼치환된-３Ｈ-옥사졸로 및３Ｈ-티아졸로 〔４，５-ｄ〕피리미딘-2-온 화합물 및 이의전구약물
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
TWI383987B (zh) 2005-11-21 2013-02-01 Anadys Pharmaceuticals Inc 製備５-胺基-３Ｈ-噻唑并〔４，５-ｄ〕嘧啶-２-酮之新穎方法
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CN101516192B (zh) 2006-06-22 2012-09-19 安那迪斯药品股份有限公司 5-氨基-3-(3'-脱氧-β-D-呋喃核糖基)-噻唑并[4,5-d]嘧啶-2,7-二酮的前药
BRPI0714831A2 (pt) 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
WO2009032057A2 (en) 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
AU2009313878B2 (en) 2008-11-13 2016-01-07 Gilead Calistoga Llc Therapies for hematologic malignancies
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
MX2011009955A (es) 2009-03-24 2011-11-18 Gilead Calistoga Llc Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
EP2421536B1 (en) 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (es) 2009-08-17 2015-08-21 Intellikine Llc
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
UY34656A (es) 2012-03-05 2013-10-31 Gilead Calistoga Llc Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
ME02400B (me) 2012-12-21 2016-09-20 Gilead Sciences Inc Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (es) 2013-07-12 2018-07-21
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN105849108A (zh) 2013-12-20 2016-08-10 吉利德卡利斯托加公司 磷脂酰肌醇3-激酶抑制剂的制备方法
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (es) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX373272B (es) 2014-07-31 2020-04-16 Novartis Ag Terapia de combinacion.
WO2018030184A1 (ja) * 2016-08-10 2018-02-15 株式会社スリーボンド エポキシ樹脂組成物およびこれを含む導電性接着剤
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN119798352B (zh) * 2024-01-15 2025-11-11 中国医学科学院药物研究所 化合物yzg-331的晶型及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
CA1239397A (en) * 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
DE3576344D1 (de) * 1984-04-18 1990-04-12 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4757747A (en) * 1986-04-08 1988-07-19 Vickers, Incorporated Power transmission
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
EP0277917A3 (en) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
DE3810551A1 (de) * 1987-04-06 1988-11-03 Sandoz Ag Neue ribofuranuronsaeure-derivate
DE68924319T2 (de) * 1988-03-16 1996-05-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
CA2028002A1 (en) * 1989-10-19 1991-04-20 Daniel P. Becker Method of treating gastrointestinal motility disorders
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
DE4025879A1 (de) * 1990-08-16 1992-02-20 Sandoz Ag Neue adenosin derivate, deren herstellung und verwendung
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
ATE206432T1 (de) * 1993-07-13 2001-10-15 Nasa A3 -adenosin -rezeptor agonisten

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237234A1 (es) * 2002-08-02 2005-07-16 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
ES2237234B1 (es) * 2002-08-02 2006-11-01 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
ES2331867A1 (es) * 2008-07-17 2010-01-18 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.
WO2010007202A1 (es) * 2008-07-17 2010-01-21 Entrechem, S.L. Sintesis enzimática de derivados enantioméricamente enriquecidos de cis- y trans-ciclopentano-1,2-diaminas
ES2331867B1 (es) * 2008-07-17 2010-10-27 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.

Also Published As

Publication number Publication date
GB9301000D0 (en) 1993-03-10
NO952872D0 (no) 1995-07-19
NO305603B1 (no) 1999-06-28
CN1119440A (zh) 1996-03-27
WO1994017090A1 (en) 1994-08-04
AP9400613A0 (en) 1994-01-31
DE69409503T2 (de) 1998-08-06
PL309975A1 (en) 1995-11-13
SK91895A3 (en) 1996-04-03
JPH08505864A (ja) 1996-06-25
TW267168B (es) 1996-01-01
AU679714B2 (en) 1997-07-10
DK0680488T3 (da) 1999-01-25
NZ259880A (en) 1996-11-26
SK281229B6 (sk) 2001-01-18
SI9400021A (en) 1994-09-30
ECSP941104A (es) 1994-12-15
RU2129561C1 (ru) 1999-04-27
IS4121A (is) 1994-07-21
EP0680488A1 (en) 1995-11-08
CA2153688A1 (en) 1994-08-04
CZ187995A3 (en) 1996-01-17
ZA94335B (en) 1994-10-24
EP0680488B1 (en) 1998-04-08
NO952872L (no) 1995-09-13
HU211914A9 (en) 1996-01-29
PE54194A1 (es) 1995-01-06
US5925624A (en) 1999-07-20
AU5885194A (en) 1994-08-15
AP457A (en) 1996-02-01
FI953489A0 (fi) 1995-07-19
IL108372A (en) 1998-06-15
JP3768232B2 (ja) 2006-04-19
KR960700261A (ko) 1996-01-19
US5889178A (en) 1999-03-30
IL108372A0 (en) 1994-04-12
DE69409503D1 (de) 1998-05-14
CN1043997C (zh) 1999-07-07
ATE164849T1 (de) 1998-04-15
FI953489A7 (fi) 1995-09-13
FI953489L (fi) 1995-09-13

Similar Documents

Publication Publication Date Title
ES2117249T3 (es) Derivados de 2,6-diaminopurina.
SE8504291L (sv) Aromatiska heterocykliska derivat och deras anvendning inom det terapeutiska och kosmetiska omradet
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
ES2172580T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
BG96180A (bg) Нови антихистаминови средства,производни на бензимидазолите
ES2094622T3 (es) Derivados triterpenos y antagonistas del receptor de endotelina que los contiene.
ES2062215T3 (es) Derivados aminoalcoxibencenicos sustituidos.
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
ES2110260T3 (es) Androstenonas.
ES2121597T3 (es) Derivados de bencenosulfonamida para el tratamiento de la inestabilidad de la vejiga.
UY25211A1 (es) Inhibidores de isoquinolinilguanidina uroquinasa
ES2059755T3 (es) Derivados organicos de hidrazina para uso farmaceutico.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
CO4410336A1 (es) Derivados de quinoxalina utiles en terapia
ES2032217T3 (es) Nuevos derivados n-(23-vinblastinoil del acido 1-amino-metilfosfonico, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
DE68906826D1 (de) Phenothiazinderivate, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES2043515A1 (es) Procedimiento para la preparacion de nuevos derivados de 1-difenilmetilpiperazina.
MX9203234A (es) Derivados de 5-halovinil-2-desoxiuridina y composiciones farmaceuticas que los contienen.
MX9204220A (es) Bencimidazoles.
ATE210135T1 (de) Antiallergische thiadiazolo(4,3- a)pyridinderivative
ES2065192T3 (es) Nuevos nicotinatos de diacil-glicerol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19950406

FG2A Definitive protection

Ref document number: 680488

Country of ref document: ES